Paul Harch, MD

Paul G. Harch, MD is an emergency medicine and hyperbaric medicine clinician who is a Clinical Professor of Medicine, Section of Emergency Medicine, at LSU School of Medicine, New Orleans, and former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship. In 1989 he adapted the wound concepts of conventional hyperbaric oxygen therapy to treat and conduct research on patients with wounds in the central nervous system. That initiative resulted in a private and academic practice with one of the largest and most diverse case experiences in neurological hyperbaric medicine in the world. This experience began with brain injured boxers and d ivers and expanded to patients with cerebral palsy, autism, drowning, Alzheimer's, traumatic brain injury, stroke, and approximately 90 adult and pediatric neurological diagnoses. His work has included a systematic review on HBOT in Persistent Postconcussion Syndrome. In March, 2020 he proposed the application of HBOT to COVID-19 pneumonia based on the successful use of hyperbaric treatment for dying Spanish Flu patients in 1918 and has now successfully treated patients with COVID-19 Long-Haulers Syndrome and COVID vaccine injury. The basis for these COVID applications is hyperbaric oxygen therapy's broad-based effects on immune dysregulation and inflammation. Dr. Harch's work and perspective on hyperbaric oxygen therapy have been published in multiple scientific articles, book chapters, and in his book, The Oxygen Revolution, where HBOT is explained as an epigenetic therapy with expected revolutionary effects on medicine and neurology.